- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07942025
90Y-SIRT as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Efficacy and Long-Term Outcomes of Yttrium-90 Treatment as Conversion Therapy for Unresectable Hepatocellular Carcinoma: A Multicenter Cohort Study
This multicenter observational study will evaluate long-term outcomes in patients with initially unresectable hepatocellular carcinoma who undergo curative-intent hepatectomy after conversion therapy. The conversion therapy is based on either yttrium-90 selective internal radiation therapy or transarterial chemoembolization. The study includes a retrospective cohort and a prospective observational cohort. The primary outcome is recurrence-free survival after surgery. Overall survival, postoperative pathological features, and perioperative outcomes will also be compared between the two groups.
Tutkimuksen yleiskatsaus
Tila
Yksityiskohtainen kuvaus
This study includes both retrospective and prospective components. The retrospective cohort will include eligible patients who previously underwent curative-intent hepatectomy after 90Y-SIRT-based or TACE-based conversion therapy. The prospective observational cohort will consecutively enroll eligible patients after curative-intent hepatectomy and follow them prospectively for postoperative outcomes.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Zheyu Zhou
- Puhelinnumero: +86 18851092739
- Sähköposti: zzys02910@btch.edu.cn
Opiskelupaikat
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kiina, 102218
- Beijing Tsinghua Changgung Hospital
-
Ottaa yhteyttä:
- Lin Zhang
- Puhelinnumero: +86 15699793366
- Sähköposti: zla02285@btch.edu.cn
-
-
Chongqing Municipality
-
Chongqing, Chongqing Municipality, Kiina, 400038
- Southwest Hospital, Army Medical University
-
Ottaa yhteyttä:
- Hui Zhang
- Puhelinnumero: +86 02368754000
- Sähköposti: 13637912611@163.com
-
-
Fujian
-
Fuzhou, Fujian, Kiina, 350025
- Mengchao Hepatobiliary Hospital of Fujian Medical University
-
Ottaa yhteyttä:
- Wuhua Guo
- Puhelinnumero: +86 059188110232
- Sähköposti: guowuhua@aliyun.com
-
-
Guangdong
-
Guangzhou, Guangdong, Kiina, 510630
- The First Affiliated Hospital of Jinan University
-
Ottaa yhteyttä:
- Chengzhi Li
- Puhelinnumero: +86 02038688888
- Sähköposti: lichengzhi@jnu.edu.cn
-
-
Liaoning
-
Shenyang, Liaoning, Kiina, 110001
- The First Hospital of China Medical University
-
Ottaa yhteyttä:
- Haibo Shao
- Puhelinnumero: +86 02483283333
- Sähköposti: haiboshao@aliyun.com
-
-
Shaanxi
-
Xi'an, Shaanxi, Kiina, 710061
- The First Affiliated Hospital of Xi'an Jiaotong University
-
Ottaa yhteyttä:
- Xin Zheng
- Puhelinnumero: +86 02985323112
- Sähköposti: xin.zheng.xjtu@gmail.com
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Näytteenottomenetelmä
Tutkimusväestö
The study population consists of patients with initially unresectable HCC treated at participating centers who undergo curative-intent hepatectomy after 90Y-SIRT-based or TACE-based conversion therapy. All consecutive patients meeting the predefined eligibility criteria will be included. Patients identified from historical records will form the retrospective cohort, while patients enrolled after study initiation will form the prospective observational cohort.
Kuvaus
Inclusion Criteria:
- Initially unresectable primary liver cancer.
- Underwent curative-intent hepatectomy following conversion therapy based on 90Y-SIRT or TACE.
- Postoperative histopathological examination confirmed HCC.
Exclusion Criteria:
- Received conversion therapy based on other locoregional treatments, such as hepatic arterial infusion chemotherapy (HAIC) or external beam radiotherapy (EBRT).
- Presence of extrahepatic metastasis prior to curative-intent hepatectomy.
- Postoperative histopathological diagnosis of intrahepatic cholangiocarcinoma (ICC) or combined hepatocellular-cholangiocarcinoma (cHCC-CCA).
- Failure to achieve R0 resection.
- Incomplete clinical data.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Havaintomallit: COHORT
- Aikanäkymät: OTHER
Kohortit ja interventiot
Ryhmä/Kohortti |
|---|
|
90Y-SIRT-Based Conversion Therapy Group
Patients with initially unresectable hepatocellular carcinoma who received conversion therapy based on yttrium-90 selective internal radiation therapy (90Y-SIRT) and subsequently underwent curative-intent hepatectomy after being deemed resectable. |
|
TACE-Based Conversion Therapy Group
Patients with initially unresectable hepatocellular carcinoma who received conversion therapy based on transarterial chemoembolization (TACE) and subsequently underwent curative-intent hepatectomy after being deemed resectable. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Aikaikkuna |
|---|---|
|
Postoperative recurrence-free survival (RFS)
Aikaikkuna: From the date of curative-intent hepatectomy until the first tumor recurrence, death, or last follow-up, up to 5 years.
|
From the date of curative-intent hepatectomy until the first tumor recurrence, death, or last follow-up, up to 5 years.
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Postoperative overall survival (OS)
Aikaikkuna: From the date of curative-intent hepatectomy until death or last follow-up, up to 10 years.
|
From the date of curative-intent hepatectomy until death or last follow-up, up to 10 years.
|
|
|
Pathological complete response (pCR) rate
Aikaikkuna: Immediately after curative-intent hepatectomy.
|
pCR is defined as the absence of residual viable tumor cells in the resected specimens. The pCR rate is calculated as the proportion of patients achieving pCR among all patients with evaluable postoperative histopathological assessments. |
Immediately after curative-intent hepatectomy.
|
|
Major pathological response (MPR) rate
Aikaikkuna: Immediately after curative-intent hepatectomy.
|
MPR is defined as ≤10% residual viable tumor cells in the resected specimens. The MPR rate is calculated as the proportion of patients achieving MPR among all patients with evaluable postoperative histopathological assessments. |
Immediately after curative-intent hepatectomy.
|
|
Microvascular invasion (MVI) positivity rate
Aikaikkuna: Immediately after curative-intent hepatectomy.
|
Immediately after curative-intent hepatectomy.
|
|
|
Satellite nodule positivity rate
Aikaikkuna: Immediately after curative-intent hepatectomy.
|
Immediately after curative-intent hepatectomy.
|
|
|
Postoperative complication rate
Aikaikkuna: Perioperatively, from curative-intent hepatectomy through hospital discharge.
|
The occurrence and type of postoperative complications will be recorded, and their severity will be graded according to the Clavien-Dindo classification. Bile leakage and post-hepatectomy liver failure (PHLF) will also be graded according to the ISGLS criteria. |
Perioperatively, from curative-intent hepatectomy through hospital discharge.
|
Muut tulostoimenpiteet
Tulosmittaus |
Aikaikkuna |
|---|---|
|
Percentage change in tumor markers
Aikaikkuna: From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
|
From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
|
|
Percentage change in maximum tumor diameter
Aikaikkuna: From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
|
From baseline before conversion therapy to the preoperative assessment before curative-intent hepatectomy.
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Päätutkija: Lin Zhang, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- KX26-0904-0317
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
De-identified IPD underlying the published results may be made available upon reasonable request after publication, subject to approval by the principal investigator and applicable ethical and institutional requirements.
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .